Valuation: Evolus, Inc.

Market Cap 528M 460M 433M 395M 740M 50.56B 741M 5.19B 2B 25.75B 1.98B 1.94B 83.11B P/E 2026 *
-16.2x
P/E 2027 * -51.2x
Enterprise Value 649M 566M 533M 485M 910M 62.15B 911M 6.38B 2.46B 31.66B 2.44B 2.38B 102B EV / Sales 2026 *
1.94x
EV / Sales 2027 * 1.67x
Free-Float
81.8%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week+0.76%
Current month-12.10%
1 month-4.77%
3 months+20.51%
6 months+72.20%
Current year+20.15%
1 week 7.76
Extreme 7.76
8.14
1 month 7.59
Extreme 7.59
9.31
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Chief Executive Officer

-105,108 0.1625%
20/03/26 Sell

Chief Executive Officer

13,669 0.0211%
20/03/26 Sell

Chief Technology Officer

3,119 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%+0.76%+27.03%-12.68% 528M
+1.04%+2.34%+54.91%+111.75% 1,038B
-0.19%+1.18%+52.94%+66.69% 649B
+0.20%+1.04%+18.88%+72.38% 467B
-0.77%+0.25%+33.35%+44.95% 355B
+0.02%+2.00%+18.13%+26.30% 269B
+0.45%+3.95%+9.51%+14.01% 260B
+1.95%+3.06%+37.75%+45.93% 213B
-0.69%-6.43%-32.63%-59.75% 176B
+0.30%+2.83%+31.97%+100.03% 187B
Average +0.26%+1.02%+25.18%+40.96% 361.56B
Weighted average by Cap. -0.12%+1.47%+35.31%+65.75%

Financials

2026 *2027 *
Net sales 334M 291M 274M 250M 469M 32.01B 469M 3.29B 1.27B 16.31B 1.26B 1.23B 52.62B 392M 342M 322M 293M 550M 37.57B 551M 3.86B 1.49B 19.14B 1.47B 1.44B 61.76B
Net income -31.58M -27.53M -25.93M -23.62M -44.28M -3.03B -44.33M -311M -120M -1.54B -119M -116M -4.97B -9.05M -7.89M -7.43M -6.77M -12.69M -867M -12.7M -88.98M -34.29M -442M -33.99M -33.23M -1.42B
Net Debt 121M 105M 99.36M 90.49M 170M 11.59B 170M 1.19B 459M 5.91B 455M 444M 19.06B 126M 110M 103M 94.23M 177M 12.07B 177M 1.24B 478M 6.15B 473M 463M 19.84B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
21/09/26 $7.990 +1.65% 420,739
18/09/26 $7.860 -1.87% 1,181,608
17/09/26 $8.010 +0.25% 1,225,162
16/09/26 $7.990 +1.01% 683,411
15/09/26 $7.910 -0.25% 637,970
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.990USD
Average target price
15.00USD
Spread / Average Target
+87.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!